Respiratory illnesses are on the rise across the country; Argenx’s antibody therapy fails a Phase 3 trial; The FDA suspects contaminated applesauce pouches were the result of a manufacturer cutting corners to save money.
Five things for pharma marketers to know for Wednesday morning
Bluebird Bio plans to raise $250 million in a stock sale and unusual financing deal; Compugen sells exclusive rights to Gilead for Anti-IL 18 binding protein antibodies; ProPublica and the Pittsburgh Post-Gazette debut With Every Breath documentary.
Five things for pharma marketers to know for Tuesday morning
Apple announces that it will soon halt sales of its flagship Apple Watch models in the U.S.; A combination of GSK cancer drugs Zejula and Jemperli meet the main goal of a late-stage trial; The best biopharma CEOs of 2023.
Five things for pharma marketers to know for Monday morning
Moderna’s investigational vaccine for RSV is 84% effective against the lower respiratory tract illness; Pfizer strikes a deal with Nona Biosciences that could reach $1.05 billion; Immusoft announces its scientists genetically programmed a patient’s B cells and put them back in his body in an effort to treat disease.
Five things for pharma marketers to know for Friday morning
WeightWatchers launches its GLP-1 program; Moderna and Merck’s experimental cancer vaccine, when used in combination with Keytruda, reduced the risk of death or relapse in patients with melanoma; The Biden administration refers to its ‘march-in’ rights proposal as putting “drug companies on notice.”
Five things for pharma marketers to know for Thursday morning
The Supreme Court agrees to review access to abortion drug mifepristone; Poison control centers say they are seeing a steep increase in calls related to semaglutide; How Pfizer’s $43 billion acquisition of Seagen may impact the broader biotech market.
Five things for pharma marketers to know for Wednesday morning
Moderna’s chief commercial officer set to leave company; Pfizer to move ahead with its $43 billion acquisition of Seagen; Walgreens eyes Boots spinoff.
Five things for pharma marketers to know for Tuesday morning
Moderna and Merck launch new study for mRNA cancer therapy in lung cancer; Cigna drops merger plans with Humana; Hoba Therapeutics raises $25 million Series A for pain and hearing loss candidates.
Five things for pharma marketers to know: Friday, December 1, 2023
AbbVie’s $10.1 billion deal for ImmunoGen lifts biotech stocks; Novo sues pharmacies over impure weight loss drugs; The WHO says the world is in danger of losing the fight against malaria.
Five things for pharma marketers to know: Wednesday, November 29, 2023
The FDA is investigating whether CAR-T therapy can, in rare cases, cause lymphoma; Biden administration urges drugmakers like Sanofi and AstraZeneca to ramp up RSV vaccine manufacturing; Novocure lays off 13% of staff as it cuts $60 million in operating expenses.
